91影库

Journal News

91影库journals will be fully open access in 2021

91影库Today Staff
May 11, 2020

Earlier today, the 91影库 and Molecular Biology announced that its three peer-reviewed journals will become, as of January, open access. You can read the announcement in full below. The society also created a page with frequently asked questions.


As elected, editorial and administrative leaders of the 91影库 and Molecular Biology, we are pleased to announce that the society’s three highly regarded journals — , and — will be fully open access beginning in January 2021.

The 91影库exists to meet the needs and respond to the demands of its members, and our members, in line with the broader scientific community, have called for immediate and free public access to research published in 91影库journals in order to reduce barriers to scientific knowledge and accelerate discoveries.

91影库journals have for years made accepted manuscripts immediately available for free as Papers in Press and have embargoed the final redacted versions of articles for subscribers for only a single year. In addition, authors have had the option to pay an additional fee for immediate open access of the final version of a paper or upload the accepted version for free to a public repository. As of January, the final versions of all articles will be immediately available to everyone, qualifying 91影库journals as “gold” open access. This is important because an increasing number of funders of biomedical research are requiring its grantees to publish in only “gold” journals.

Our decision-making process was careful and consultative. During our months-long deliberations, we had to balance what is best for science and scientists with what is sustainable for a nonprofit organization. Ultimately, we determined that the 91影库cannot achieve its goal of full open access alone, so we made the strategic decision to enter into an agreement with the commercial publisher , which has experience transitioning subscription journals to full open access and the requisite technical expertise and infrastructure.

We want to emphasize that this agreement will not change the peer-review process at any of our journals. JBC, MCP and JLR remain committed to rigorous, fast and fair review — by active scientists.

We are happy to report, also, that the agreement will smooth the submission process for authors and reduce the cost of open-access publishing — for both members and nonmembers alike. It also will make our journals easier to read on mobile devices, discoverable on the platform ScienceDirect and, generally speaking, more nimble technologically.

Transitioning from a subscription model to an open-access model is complicated, but we know this is the right decision for the ASBMB. Throughout our deliberations, we kept focused on our goal: to make the high-quality papers we publish immediately and permanently available for everyone to read, download, copy and distribute.

We will share more information on the transition in the months to come. In the meantime, we hope that you will reach out to us if you have any questions or concerns.

Sincerely,

Gerald Hart (President, ASBMB)
Joan Conaway (Treasurer, ASBMB)
Sandra Weller (Chair, 91影库Publications Committee)
Toni Antalis (President-elect, ASBMB)
Lila M. Gierasch (Editor-in-Chief, Journal of Biological Chemistry)
Alma Burlingame (Editor-in-Chief, Molecular & Cellular Proteomics)
Kerry-Anne Rye and Nicholas O. Davidson (Co-Editors, Journal of Lipid Research)
Barbara Gordon (Executive Director, ASBMB)
Nancy Rodnan (Senior Director, 91影库Publications)
Steve Miller (Deputy Executive Director and Chief Financial Officer, ASBMB)

Enjoy reading 91影库Today?

Become a member to receive the print edition four times a year and the digital edition monthly.

Learn more
91影库Today Staff

This article was written by a member or members of the 91影库Today staff.

Related articles

A year of open access
Nicholas O. Davidson, Kerry-Anne Rye & Alex Toker
Cervical Health Awareness Month
Vaishnavi Muralikrishnan

Get the latest from 91影库Today

Enter your email address, and we鈥檒l send you a weekly email with recent articles, interviews and more.

Latest in Science

Science highlights or most popular articles

Hope for a cure hangs on research
Essay

Hope for a cure hangs on research

July 17, 2025

Amid drastic proposed cuts to biomedical research, rare disease families like Hailey Adkisson鈥檚 fight for survival and hope. Without funding, science can鈥檛 鈥渃atch up鈥 to help the patients who need it most.

Before we鈥檝e lost what we can鈥檛 rebuild: Hope for prion disease
Feature

Before we鈥檝e lost what we can鈥檛 rebuild: Hope for prion disease

July 15, 2025

Sonia Vallabh and Eric Minikel, a husband-and-wife team racing to cure prion disease, helped develop ION717, an antisense oligonucleotide treatment now in clinical trials. Their mission is personal 鈥 and just getting started.

Defeating deletions and duplications
News

Defeating deletions and duplications

July 11, 2025

Promising therapeutics for chromosome 15 rare neurodevelopmental disorders, including Angelman syndrome, Dup15q syndrome and Prader鈥揥illi syndrome.

Using 'nature鈥檚 mistakes' as a window into Lafora disease
Feature

Using 'nature鈥檚 mistakes' as a window into Lafora disease

July 10, 2025

After years of heartbreak, Lafora disease families are fueling glycogen storage research breakthroughs, helping develop therapies that may treat not only Lafora but other related neurological disorders.

Cracking cancer鈥檚 code through functional connections
News

Cracking cancer鈥檚 code through functional connections

July 2, 2025

A machine learning鈥揹erived protein cofunction network is transforming how scientists understand and uncover relationships between proteins in cancer.

Gaze into the proteomics crystal ball
In-person Conference

Gaze into the proteomics crystal ball

July 1, 2025

The 15th International Symposium on Proteomics in the Life Sciences symposium will be held August 17鈥21 in Cambridge, Massachusetts.